Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial

Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial

Abstract Metformin may exert anticancer effects through indirect (mediated by metabolic changes) or direct mechanisms. The goal was to examine metformin impact on metabolic factors in non-diabetic subjects and determine whether this impact varies by baseline BMI, insulin, and rs11212617 SNP in CCTG...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Pamela J. Goodwin, Ryan J. O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Margot J. Burnell, Rachel Vander Meer, Andrea Molckovsky, Anagha Gurjal, Karen A. Gelmon, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Whelan, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alastair M. Thompson, Daniel W. Rea, Vuk Stambolic
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/ed8c22cdd63b4d8ab3a69bbf18ba9909
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/ed8c22cdd63b4d8ab3a69bbf18ba9909

Documents similaires